MedTrace Logo

Insulin-based Strategies to Prevent Hypoglycemia During Two Types of Exercise

NCT03845114 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-11-06

No results posted yet for this study

Summary

Regular exercise is associated with many health benefits for individuals with type 1 diabetes. However, immediate and delayed exercise-induced hypoglycemia is frequent and thus the main limiting factor for physical activity practice in this population. To reduce the risk of exercise-induced hypoglycemia, two types of adjustments may be considered by patients with type 1 diabetes : pre-meal insulin-dose reduction and carbohydrate supplements. Few evidence-based recommendations are available for patients using insulin pump to adjust insulin doses in order to limit exercise-induced hypoglycemia. The objective of this study is to address the magnitude of the needed reduction during two types of frequently practiced exercise (continuous vs. interval exercise) known to have a different impact on blood glucose reduction.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

OTHER

Continous exercise

60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).

OTHER

Interval exercise

Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).

OTHER

Reduction of basal insulin by 40%

Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.

OTHER

Reduction of basal insulin by 80%

Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER

  • Institut de Recherches Cliniques de Montreal

    lead OTHER

Principal Investigators

  • Rémi Rabasa-Lhoret · Institut de recherches cliniques de Montréal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2023-12-15
Completion
2024-08-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03845114 on ClinicalTrials.gov